ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a real-world study of postmenopausal women with high-risk osteoporosis, abaloparatide and romosozumab significantly improved bone mineral density and threedimensional hip structural parameters over 12 months, with no significant between-group differences observed. PURPOSE: Direct real-world comparisons between abaloparatide and romosozumab, particularly incorporating structural assessment beyond areal bone mineral density (BMD), remain limited.
methodsThis nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were included in each group. Primary endpoints were percentage changes in lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD over 12 months. Secondary and exploratory endpoints included achievement of T-score thresholds, bone turnover markers, and DXA-based 3D-Shaper structural parameters. Longitudinal changes were assessed using mixed models for repeated measures.
resultsBoth groups demonstrated significant increases in BMD at all skeletal sites at 12 months (all P < 0.001), with no significant between-group differences. The proportion of patients achieving a T-score > -2.5 increased over time in both groups without significant between-group differences. Exploratory 3D-Shaper analyses demonstrated improvements in several trabecular and cortical structural parameters over 12 months, with no significant between-group differences in any parameter.
conclusionIn this real-world propensity score-matched cohort, abaloparatide and romosozumab significantly improved BMD and proximal femur structural parameters over the first 12 months of treatment. No significant between-group differences were observed during this period.
Indexed as
Identifiers
42803810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.